Jeune Aesthetics Announces Positive Durability Results for KB301 in the PEARL-1 Extension Cohort, an Investigational Gene-based Treatment for Improvement of Fine Lines and WrinklesGlobeNewsWire • 11/17/22
Krystal Biotech Announces Third Quarter 2022 Financial Results and Operational HighlightsGlobeNewsWire • 11/07/22
Krystal Biotech to Present at Chardan's 6th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/29/22
Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric Investigation Plan for B-VEC for the treatment of Dystrophic Epidermolysis BullosaGlobeNewsWire • 09/21/22
Krystal Biotech to Present at H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewsWire • 09/08/22
FDA Accepts Krystal Biotech's Biologics License Application for Dystrophic Epidermolysis BullosaGlobeNewsWire • 08/18/22
Krystal Biotech Announces Second Quarter 2022 Financial Results and Reports Updates on Operational ProgressGlobeNewsWire • 08/08/22
Krystal Biotech Announces FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical TrialGlobeNewsWire • 08/01/22
Krystal Biotech Receives FDA Acceptance of KB407 IND Application for Cystic Fibrosis Clinical TrialGlobeNewsWire • 08/01/22
Krystal Biotech Submits Biologics License Application to U.S. FDA Seeking Approval of B-VEC for the Treatment of Patients with Dystrophic Epidermolysis BullosaGlobeNewsWire • 06/22/22
Krystal Biotech to Present at Goldman Sachs 43rd Annual Global Healthcare ConferenceGlobeNewsWire • 06/07/22
Krystal Biotech to Present Additional Data on B-VEC from the GEM-3 Phase 3 Study at the Society for Investigative Dermatology Annual MeetingGlobeNewsWire • 05/19/22
Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/09/22
Krystal Biotech Announces First Quarter 2022 Financial Results and Reports Updates on Operational ProgressGlobeNewsWire • 05/09/22
Krystal Biotech to Participate in Bank of America Merrill Lynch Global Healthcare ConferenceGlobeNewsWire • 05/03/22
Krystal Biotech Announces Publication of Phase 1 and 2 Clinical Trial (GEM 1/2 Study) of Beremagene Geperpavec (B-VEC) Data in Nature MedicineGlobeNewsWire • 03/28/22
New GEM-3 Phase 3 Results for B-VEC Presented at 2022 American Academy of Dermatology Annual MeetingGlobeNewsWire • 03/26/22